Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial - Concepedia

Concepedia

Publication | Closed Access

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

557

Citations

14

References

2002

Year

Unknown Author(s)

OncologyMedicineSingle-agent CarboplatinMetronomic TherapyGynecologyPharmacotherapyCancer TreatmentPharmacologyGynecology OncologyOvarian Cancer

References

	Year	Citations

Page 1